[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Curis Inc (CRIS)

Curis Inc (CRIS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 3,595
  • Shares Outstanding, K 2,090
  • Annual Sales, $ 9,440 K
  • Annual Income, $ -7,580 K
  • EBIT $ -34 M
  • EBITDA $ -34 M
  • 60-Month Beta 3.13
  • Price/Sales 0.38
  • Price/Cash Flow N/A
  • Price/Book 0.71

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 4 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/26
See More
  • Average Estimate $-2.29
  • Number of Estimates 1
  • High Estimate $-2.29
  • Low Estimate $-2.29
  • Prior Year $-9.80
  • Growth Rate Est. (year over year) +76.63%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.5400 +4.55%
on 08/13/26
5.6000 -71.25%
on 07/30/26
-2.9100 (-64.38%)
since 07/20/26
3-Month
1.5400 +4.55%
on 08/13/26
11.4060 -85.88%
on 05/29/26
-8.2940 (-83.74%)
since 05/20/26
52-Week
1.5400 +4.55%
on 08/13/26
39.0000 -95.87%
on 09/11/25
-29.3900 (-94.81%)
since 08/20/25

Most Recent Stories

More News
Curis: Q2 Earnings Snapshot

Curis: Q2 Earnings Snapshot

CRIS : 1.6100 (-6.40%)
Curis, Inc. Announces Pricing of $5.6 Million Public Offering

LEXINGTON, Mass. , Aug. 13, 2026 /PRNewswire/ -- Curis, Inc. (Nasdaq: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4...

CRIS : 1.6100 (-6.40%)
Curis Doses First Five Patients in TakeAim CLL Study

LEXINGTON, Mass. , July 30, 2026 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4...

CRIS : 1.6100 (-6.40%)
Curis Announces Positive Emavusertib Update

Updated Clinical Data in PCNSL

CRIS : 1.6100 (-6.40%)
Curis Consents First Six Patients in TakeAim CLL Study

LEXINGTON, Mass. , July 6, 2026 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4...

CRIS : 1.6100 (-6.40%)
Curis Announces Eleven Active Clinical Sites in TakeAim CLL Study, Reaffirms Patient Dosing Guidance, and Reports Stockholder Approval of Reverse Stock Split

Eleven sites open for patient enrollment in TakeAim CLL combination study with zanubrutinib; Company reaffirms guidance for dosing of initial five patients by end of July 2026 with data expected December...

CRIS : 1.6100 (-6.40%)
Curis: Q1 Earnings Snapshot

Curis: Q1 Earnings Snapshot

CRIS : 1.6100 (-6.40%)
Curis Provides First Quarter 2026 Business Update

Management to host conference call today at 4:30 p.m. ET

CRIS : 1.6100 (-6.40%)
Curis to Report First Quarter 2026 Financial and Operating Results and Host Conference Call and Webcast on May 12, 2026

LEXINGTON, Mass. , May 5, 2026 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 and...

CRIS : 1.6100 (-6.40%)
Curis: Q4 Earnings Snapshot

Curis: Q4 Earnings Snapshot

CRIS : 1.6100 (-6.40%)

Business Summary

Curis, Inc. is a therapeutic drug development company focusing on cancer, neurological and dermatological disease indications, with technologies that utilize regulatory pathways that control repair and regeneration. Curis' product development involves the use of small molecules or proteins to modulate...

See More

Key Turning Points

3rd Resistance Point 1.8117
2nd Resistance Point 1.7633
1st Resistance Point 1.6867
Last Price 1.6100
1st Support Level 1.5617
2nd Support Level 1.5133
3rd Support Level 1.4367

See More

52-Week High 39.0000
Fibonacci 61.8% 24.6903
Fibonacci 50% 20.2700
Fibonacci 38.2% 15.8497
Last Price 1.6100
52-Week Low 1.5400

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.